(CercleFinance.com) – Roche today presented positive results from a phase III study evaluating inavolisib (an experimental oral treatment) combined with palbociclib (Ibrance®) and fulvestrant as first-line treatment for people with breast cancer (HR+/HER2-) resistant to the endocrine system, locally advanced or metastatic.
Adding inavolisib to the care regimen reduced the risk of disease worsening or death (progression-free survival) by 57% compared to palbociclib and fulvestrant alone.
If the laboratory specifies that the overall survival (OS) data was immature at that time, it indicates ‘that a clear positive trend was observed’.
Data available for other secondary endpoints in this analysis showed clinically meaningful increases in objective response rate, duration of response and clinical benefit rate, Roche adds.
The study data will be submitted to health authorities with a view to offering this potential therapeutic option to patients as soon as possible.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
